What is the main change reported in this 8-K filing?

The main change is the amendment to CME Group's Bylaws, specifically Article III, Section 3.5, regarding the composition requirements of the Board of Directors. It replaces specific diversity of interest requirements from the trading community with a general consideration of CFTC board composition requirements.

Why did CME Group amend its Bylaws?

The amendment was made to align the company's bylaws with current regulatory oversight by the Commodity Futures Trading Commission (CFTC), making the board composition requirements more generalized to accommodate CFTC's directives.

What is the role of the Nominating Committee after this amendment?

The Nominating Committee, along with the Board, is now tasked with considering applicable CFTC board composition requirements. Additionally, the Nominating Committee is required to include the Company's Executive Chairman and President as nominees.

Does this change impact the day-to-day operations of CME Group?

This is primarily a corporate governance and regulatory compliance update. While it affects the structure and nomination process for the Board of Directors, it is unlikely to have a direct, immediate impact on the day-to-day trading operations or customer-facing services of CME Group.

CME 8-K: Corporate Changes

Summary

CME Group Inc. (CME) filed an 8-K on November 14, 2012, to report an amendment to its Bylaws, approved by the Board of Directors on November 7, 2012. The primary change involves Article III, Section 3.5, which previously detailed specific board composition requirements related to the diversity of interests from its trading community. This specific requirement has been replaced with a more general mandate that the Nominating Committee and the Board will consider applicable board composition requirements set by the Commodity Futures Trading Commission (CFTC).

Key Highlights

1CME Group amended its Bylaws concerning board composition requirements.
2The amendment shifts focus from specific trading community interest diversity to CFTC regulatory requirements.
3The Nominating Committee and Board will now consider CFTC's board composition rules.
4The Company's Executive Chairman and President will be included as nominees by the Nominating Committee.
5The change reflects an adaptation to regulatory oversight by the CFTC.
6This filing is a procedural update concerning corporate governance and regulatory compliance.
7The full text of the Amended and Restated Bylaws is attached as Exhibit 3.1 to the filing.

CME GROUP INC. 8-K Report, Bylaw Amendment (Nov 14, 2012)

Summary

Key Highlights

Frequently Asked Questions